Lupus & antiphospholipid syndrome
Mesenchymal Stromal Cell Therapy Alleviates Lupus Nephritis Through Inhibiting Caspase‐4/5/11–Mediated Noncanonical Pyroptosis in Macrophages
Authors' conclusion
Our findings showed that MSCT ameliorates LN by inhibiting the caspase-4/5/11-mediated pyroptosis in macrophages, possibly via secreting galectin-3 and IL-10.
Study context
- Population
- Patients and mice with lupus nephritis (LN); 19 patients with refractory SLE receiving MSC transplantation (MSCT); MRL/lpr micerefractory SLE receiving MSCT
- Participants
- 19 patients
Methodological detailshuman samples and MRL/lpr mouse model, in vitro coculture
- Human samples and MRL/lpr mouse model
- In vitro coculture
Main finding
As reported in the abstract
- Noncanonical pyroptosis signaling activated in macrophages and kidney tissues from humans and mice with LN
- Caspase-4 expression increased and positively correlated with active and chronic index in kidneys of patients with LN
- End products of pyroptosis directly induced cell death and reduced functional markers expression in murine podocytes
- Caspase-11 inhibitor effectively alleviated renal damage in lupus mice
- MSCT significantly deactivated pyroptosis signaling in patients and lupus-prone mice
- Galectin-3 and IL-10 essential for mesenchymal stromal cells (MSCs) to inhibit noncanonical pyroptosis of LN macrophages
Original publication
Mesenchymal Stromal Cell Therapy Alleviates Lupus Nephritis Through Inhibiting Caspase‐4/5/11–Mediated Noncanonical Pyroptosis in Macrophages. Arthritis Rheumatol. Published 19 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →